Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tracking superbugs from mother to baby: a chicago study

NCT ID NCT06148480

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study looks at how drug-resistant bacteria, specifically ESBL-producing E. coli, are passed from mothers to their newborns during vaginal birth or scheduled C-sections. Researchers will test stool samples from 200 healthy mothers and their babies at a Chicago hospital to see how common these bacteria are and how often they are transmitted. By comparing the bacteria's genes, they hope to find what makes some strains better at spreading, which could lead to future ways to prevent infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify genetic targets to reduce the spread of drug-resistant bacteria from mother to baby.
What could go wrong
This is an observational study, not a treatment trial. It may not lead directly to new therapies, and findings may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Jul 2020

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Mothers and their infants born vaginally or by scheduled c-section and who are admitted to Northwestern Medicine Prentice Women's Hospital

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women that are admitted to Northwestern Medicine Women's Hospital that have delivered an infant vaginally or have had a scheduled C-section without preceding labor. * Infants that are born vaginally who are healthy and do not require transfer to the NICU for any reason. Exclusion Criteria: * Temperature \>38 Celsius in labor * Caesarean section after labor * Rupture of membranes or done emergently * Antibiotic use in last trimester including for GBS+ * Delivery at \<35 weeks * Immunocompromised host including being HIV+ * Infant requiring transfer to NICU for any reason and infants who are transferred to the NICU.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for E. coli infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Prentice Women's Hospital

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.